# 2026-12933: FDA Hits Snooze Button on 1970s Hormone Drug Review

2026-12933, Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-06-26, effective 2026-09-24; PRIA reads it as touching household money (as of 2026-07-03).

- Canonical: https://policyrisk.com/federal-register/2026-12933
- As of: 2026-07-03
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-12933
- Title: Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 38717
- Published: 2026-06-26
- Effective: 2026-09-24
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-07-03

## In one line

FDA Hits Snooze Button on 1970s Hormone Drug Review

## Summary

The FDA is giving itself 90 more days—until September 24, 2026—to finish reviewing important feedback about certain estrogen-androgen combo drugs like Syntest tablets. This means the final decisions about these drugs’ approval are on hold a bit longer, affecting drug makers and patients waiting for updates. No extra costs are mentioned, just more time to get it right!

## Abstract

The Food and Drug Administration (FDA, Agency, or we) is extending the effective date of the notice published in the Federal Register on May 27, 2026, titled Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Syntest D.S. and Syntest H.S. Tablets; Withdrawal of Hearing Requests; Final Resolution of Drug Efficacy Study Implementation 7661 (91 FR. 31462) (the "May 2026 Notice"), by 90 days. The effective date of the May 2026 Notice is hereby extended from June 26, 2026, to September 24, 2026. This extension is necessary to allow FDA sufficient time to consider issues raised by interested parties following publication of the May 2026 Notice.

## Effects PRIA read

- FDA delays enforcement 90 days: benefit, medium. The FDA is giving itself 90 more days — moving the effective date from June 26, 2026, to September 24, 2026 — to consider comments on estrogen-androgen fixed-combination drug products (including those discussed for Syntest tablets). That means the FDA will not implement the May 27, 2026, final reso…
- Unapproved products become unlawful: cost, medium. The May 27, 2026, final resolution found that estrogen-androgen fixed-combination drug products lack substantial evidence of effectiveness for treating moderate to severe vasomotor symptoms in patients not improved by estrogen alone, and shipment in interstate commerce of any identified or identica…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-12933 on federalregister.gov](https://www.federalregister.gov/documents/2026/06/26/2026-12933/drugs-for-human-use-drug-efficacy-study-implementation-estrogen-androgen-fixed-combination-drug)
- [2026-12933 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-06-26/pdf/2026-12933.pdf)

## Related
- [Previous: 2026-12931, Formations of, Acquisitions by, and Mergers of Bank Holding Companies](https://policyrisk.com/federal-register/2026-12931)
- [Next: 2026-12936, Change in Bank Control Notices; Acquisitions of Shares of a Bank or Bank Holdin…](https://policyrisk.com/federal-register/2026-12936)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-12933 (as of 2026-07-03).
